OSE Immunotherapeutics' Tedopi® Shows Promise in Ovarian Cancer Phase 2 Trial
Event summary
- OSE Immunotherapeutics' Tedopi® Phase 2 trial results in ovarian cancer selected for oral presentation at ASCO 2026.
- TEDOVA trial evaluates Tedopi® as maintenance treatment alone or with Keytruda® vs. best supportive care in 185 patients.
- Primary endpoint is Progression-Free Survival (PFS) in platinum-sensitive recurrent ovarian cancer.
- Results to be presented by Alexandra Leary, MD, PhD, Lead Investigator of the TEDOVA trial.
The big picture
The presentation of Tedopi® Phase 2 results at ASCO 2026 highlights the growing interest in neo-epitope-based vaccines for ovarian cancer maintenance therapy. This trial is part of a broader trend in immuno-oncology to develop targeted therapies that extend survival benefits for patients with recurrent cancers. The collaboration with ARCAGY-GINECO and ENGOT underscores the importance of academic and industry partnerships in advancing clinical research.
What we're watching
- Clinical Efficacy
- Whether Tedopi® demonstrates superior Progression-Free Survival compared to best supportive care.
- Combination Therapy
- The impact of combining Tedopi® with Keytruda® on treatment outcomes.
- Regulatory Pathway
- The pace at which OSE Immunotherapeutics can advance Tedopi® into Phase 3 trials based on these results.
Related topics